Plus Therapeutics stock rating upgraded to Buy by D. Boral Capital

Investing.com - D. Boral Capital upgraded Plus Therapeutics Inc. (NASDAQ:PSTV) from Hold to Buy and set a price target of $5.00, representing significant upside potential from the current price of $0.43. According to InvestingPro data, the company maintains a positive cash position relative to its debt obligations, despite its small $42.43 million market capitalization.

The upgrade comes four months after D. Boral Capital downgraded the stock on May 5, 2025, due to concerns about a potential reverse split of the company’s shares.

According to D. Boral Capital, those reverse split concerns "may have faded" for the moment, contributing to the improved outlook for the stock.

The research firm also cited progress in Plus Therapeutics’ diagnostics division as a factor in the rating change, noting potential catalysts from an upcoming diagnostics launch.

D. Boral Capital expects these developments could help push Plus Therapeutics stock back above the $1.00 threshold, which is considered a critical price level for the company. For deeper insights into PSTV’s financial health and growth prospects, access the comprehensive Pro Research Report available exclusively on InvestingPro.

In other recent news, Plus Therapeutics, Inc. has regained compliance with Nasdaq’s listing requirements, as confirmed by The Nasdaq Stock Market LLC. The company now meets the Market Value of Listed Securities standard, requiring at least $35 million in market value, and the stockholders’ equity threshold of at least $2.5 million. As of June 30, 2025, Plus Therapeutics reported stockholders’ equity of $3 million, surpassing the minimum requirement needed to maintain its listing. Additionally, Nasdaq has granted the company an extension until November 12, 2025, to comply with the $1.00 minimum bid price rule, extending the original deadline of September 8, 2025. In other developments, Plus Therapeutics presented positive results from a retrospective analysis of its CNSide Cerebrospinal Fluid Assay Platform at a recent conference. The study involved 613 assays across five institutions, detecting tumor cells in 67% of patients. The company had previously faced a delisting determination due to a stockholders’ deficit reported as of March 31, 2025. However, the recent compliance achievements have allowed Plus Therapeutics to maintain its Nasdaq listing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.